MFDS Approves 13 New Medical Products in Q2
[Asia Economy Reporter Cho Hyun-ui] The Ministry of Food and Drug Safety announced on the 14th that a total of 13 new medical products were approved in the second quarter of this year.
The approved items include ▲5 new drugs (3 chemical, 2 bio) ▲7 orphan drugs (5 chemical, 2 bio) ▲1 newly developed medical device.
By indication, anticancer drugs were the most numerous with 6 items, including non-small cell lung cancer (Rozlytrek capsules) and prostate cancer (Nubecka tablets). Additionally, drugs for rheumatoid arthritis (Rinvoq extended-release tablets), Parkinson's disease (Equpina tablets), and macular degeneration treatment (Bioview injection) were approved.
In the medical device field, the HeartMate 3™, a mechanical circulatory support device used for patients with end-stage left ventricular heart failure, was approved.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
The Ministry of Food and Drug Safety stated, "In a situation where the whole world is facing difficulties due to the spread of the novel coronavirus infection (COVID-19), we will conduct thorough and prompt reviews to ensure that medical products with secured safety and quality can be supplied as soon as possible."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
